These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124 [TBL] [Abstract][Full Text] [Related]
5. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. Ravi A; Butterfield J; Weiler CR J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370 [TBL] [Abstract][Full Text] [Related]
6. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Picard M; Giavina-Bianchi P; Mezzano V; Castells M Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289 [TBL] [Abstract][Full Text] [Related]
7. [Idiopathic mast cell activation syndrome]. van Daele PLA; Hermans MAW; Oude Elberink JHNG; van Wijk RG Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35129899 [TBL] [Abstract][Full Text] [Related]
8. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders. Zaghmout T; Maclachlan L; Bedi N; Gülen T J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692 [TBL] [Abstract][Full Text] [Related]
9. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study. Buttgereit T; Gu S; Carneiro-Leão L; Gutsche A; Maurer M; Siebenhaar F Allergy; 2022 Sep; 77(9):2794-2802. PubMed ID: 35364617 [TBL] [Abstract][Full Text] [Related]
11. Mast Cell Activation Syndrome: A Primer for the Gastroenterologist. Weinstock LB; Pace LA; Rezaie A; Afrin LB; Molderings GJ Dig Dis Sci; 2021 Apr; 66(4):965-982. PubMed ID: 32328892 [TBL] [Abstract][Full Text] [Related]
12. Using the Right Criteria for MCAS. Gulen T Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020 [TBL] [Abstract][Full Text] [Related]
13. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview. Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME; J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851 [TBL] [Abstract][Full Text] [Related]
18. Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders. Kurin M; Elangovan A; Alikhan MM; Al Dulaijan B; Silver E; Kaelber DC; Cooper G Neurogastroenterol Motil; 2022 May; 34(5):e14265. PubMed ID: 34535952 [TBL] [Abstract][Full Text] [Related]
19. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. Kim JH; Xi S; Ference EH; Ge M; Liu MM; Wrobel BB Int Forum Allergy Rhinol; 2020 Aug; 10(8):996-1000. PubMed ID: 32407593 [TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Hahn HP; Hornick JL Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]